Vicenza Hospital Becomes First European Facility to Purchase Its Second CyberKnife System

New Unit Will Enable Italian Hospital to Expand Radiosurgery to Treat Lung and Prostate Cancer

SUNNYVALE, Calif., Nov. 25 /PRNewswire-FirstCall/ -- Accuray Incorporated (Nasdaq: ARAY), a global leader in the field of radiosurgery, announced today that Vicenza Hospital, Ospedale Civile San Bortolo in Italy has become the first European hospital to purchase a second CyberKnife(R) Robotic Radiosurgery System.

"As the clinical benefits of CyberKnife radiosurgery have evolved beyond brain and spine tumors into extracranial applications, such as lung and prostate, we have seen the number of radiosurgery cases increase significantly over the past few years. With the purchase of a second CyberKnife System, we will be able to meet this high demand for precise, accurate radiosurgical treatment throughout the body while still maintaining short waiting times for our patients with intracranial and spine tumors, and AVMs," said Professor Federico Colombo, Director of the Neurosurgical Department at Vicenza Hospital. "The CyberKnife's ability to deliver accurate radiosurgical treatments quickly and easily anywhere in the body was a decisive factor in choosing our second system."

In 2003, Vicenza Hospital was the first facility in Europe to install a CyberKnife System, which has been used primarily to treat arteriovenous malformations (AVM) and benign tumors in the brain such as neuromas and meningiomas. To date, the hospital, which is located in the Venetian region of Italy, has treated almost 1,800 patients with the CyberKnife System.

"As CyberKnife radiosurgery has evolved to address tumors anywhere in the body, demand for the treatment often becomes more than a single CyberKnife System can accommodate," said Euan S. Thomson, Ph.D., president and CEO of Accuray. "Vicenza Hospital's expansion echoes a trend we have been witnessing in the United States, in which facilities require multiple CyberKnife Systems to manage growing patient demand and expanded treatment offerings, including tumors in the lungs, prostate, pancreas, kidney or liver."

About the CyberKnife(R) Robotic Radiosurgery System

The CyberKnife Robotic Radiosurgery System is the world's only robotic radiosurgery system designed to treat tumors anywhere in the body non-invasively. Using continual image guidance technology and computer controlled robotic mobility, the CyberKnife System automatically tracks, detects and corrects for tumor and patient movement in real-time throughout the treatment. This enables the CyberKnife System to deliver high-dose radiation with pinpoint precision, which minimizes damage to surrounding healthy tissue and eliminates the need for invasive head or body stabilization frames.

About Accuray

Accuray Incorporated (Nasdaq: ARAY), based in Sunnyvale, Calif., is a global leader in the field of radiosurgery dedicated to providing an improved quality of life and a non-surgical treatment option for those diagnosed with cancer. Accuray develops and markets the CyberKnife Robotic Radiosurgery System, which extends the benefits of radiosurgery to include extracranial tumors, including those in the spine, lung, prostate, liver and pancreas. To date, the CyberKnife System has been used to treat more than 50,000 patients worldwide and currently more than 145 systems have been installed in leading hospitals in the Americas, Europe and Asia. For more information, please visit http://www.accuray.com.

Safe Harbor Statement

The foregoing may contain certain forward-looking statements that involve risks and uncertainties, including uncertainties associated with the medical device industry. Except for the historical information contained herein, the matters set forth in this press release, including statements relating to clinical studies, regulatory review and approval, and commercialization of products are forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements speak only as of the date the statements are made and are based on information available at the time those statements are made and/or management's good faith belief as of that time with respect to future events. You should not put undue reliance on any forward-looking statements. Important factors that could cause actual performance and results to differ materially from the forward-looking statements we make include: market acceptance of products; competing products, the combination of our products with complementary technology; and other risks detailed from time to time under the heading "Risk Factors" in our report on Form 10-K for the year ended June 30, 2008 as updated from time to time by our quarterly reports on Form 10-Q and our other filings with the Securities and Exchange Commission. The Company's actual results of operations may differ significantly from those contemplated by such forward-looking statements as a result of these and other factors. We assume no obligation to update forward-looking statements to reflect actual performance or results, changes in assumptions or changes in other factors affecting forward-looking information, except to the extent required by applicable securities laws.

SOURCE Accuray Incorporated
11/25/2008
CONTACT: Susan Lehman of Rockpoint Public Relations, +1-510-832-6006,
susan@rockpointpr.com, for Accuray Incorporated; or Stephanie Tomei, Manager,
Public Relations of Accuray Incorporated, +1-408-789-4234, stomei@accuray.com
Web site: http://www.accuray.com